As of June 2, 2018, the law requires that audio description for the blind and visually impaired be made available by all digital first-run movie theaters. Almost all applicable theaters have complied, and others are in the process of converting to digital and upgrading to include description equipment. The Federal Government defines audio description as […]
Genentech has announced positive, top line results from a Phase 2 study of its Port Delivery System (PDS) with Lucentis in people with wet age-related macular degeneration (AMD). The small, refillable eye implant, which is slightly longer than a grain of rice, is designed to allow people with wet AMD to go several months without […]
Allergan and Molecular Partners have announced the release of two positive clinical trials of a new treatment for wet age-related macular degeneration (wAMD). The trials, named SEQUOIA and CEDAR, demonstrated that the biological drug Abicipar is equal to Genentech’s Lucentis (ranibizumab), with the added benefit that Abicipar treatments are effective at up to 12-week dosages. […]
Age-related macular degeneration (AMD) is the most common cause of visual impairment in people over age 60. Because it affects millions of senior adults, it deserves a great deal of attention. Another common condition also deserving of consideration is dry eye. Dry eye often accompanies AMD, but only because it most commonly affects the same […]
Prevent Blindness wants all Americans to know that 14% of all injuries from fireworks are to the eyes, and that contusions, lacerations, and foreign bodies in the eyes occurred more frequently than burns to other parts of the body. Here are more important statistics from the U.S. Consumer Product Safety Commission: Fireworks devices were involved […]